COGNITION THERAPEUTICS INC 8-K

What Happened Cognition Therapeutics, Inc. (CGTX) announced on January 27, 2026 that it completed a Type C meeting with the U.S. Food and Drug Administration regarding zervimesine for the treatment of dementia with Lewy bodies. The company filed a press release about the meeting as Exhibit 99.1 to its Form 8‑K (Item 8.01).

Key Details

• Company: Cognition Therapeutics, Inc. (CGTX)
• Event: Completion of FDA Type C meeting for zervimesine
• Indication: Dementia with Lewy bodies
• Filing: Press release dated January 27, 2026 filed as Exhibit 99.1 to Form 8‑K

Why It Matters This 8‑K notifies investors that Cognition has completed a formal regulatory meeting with the FDA about its zervimesine program. A Type C meeting is a recognized regulatory interaction that can convey the FDA’s feedback on clinical development or regulatory pathway; investors should watch for any follow‑up disclosures from the company about FDA feedback or next steps.